Laryngeal mucous membrane pemphigoid serves as a prognostic factor for poor response to treatment with rituximab.
Aged
Aged, 80 and over
Fatal Outcome
Female
Humans
Immunologic Factors
/ administration & dosage
Infusions, Intravenous
Laryngeal Diseases
/ complications
Middle Aged
Mucous Membrane
/ pathology
Pemphigoid, Benign Mucous Membrane
/ diagnosis
Predictive Value of Tests
Prognosis
Recurrence
Remission Induction
Rituximab
/ administration & dosage
Sepsis
/ complications
Treatment Outcome
Journal
Clinical and experimental dermatology
ISSN: 1365-2230
Titre abrégé: Clin Exp Dermatol
Pays: England
ID NLM: 7606847
Informations de publication
Date de publication:
Jul 2021
Jul 2021
Historique:
revised:
21
03
2021
received:
13
01
2021
accepted:
30
03
2021
pubmed:
4
4
2021
medline:
30
11
2021
entrez:
3
4
2021
Statut:
ppublish
Résumé
Mucous membrane pemphigoid (MMP) is an autoimmune blistering, scarring and occasionally mutilating disease that may progress to blindness or airway obstruction. Over the past few years, rituximab (RTX) has emerged as a potential therapeutic solution for MMP; however, the literature regarding its efficacy in the treatment of severe MMP is sparse. We studied four patients with recalcitrant MMP who were treated with RTX. Three of these had recalcitrant laryngeal disease; two were unresponsive to RTX, while the third patient achieved complete remission (CR) but relapsed twice. The fourth patient, who had oral and ocular disease, also achieved CR. In addition, we reviewed 143 cases of MMP treated with RTX reported in the literature to date. Of these, 120 had late observation endpoints, of whom 81 (67.5%) achieved CR, 24 (20%) received partial remission and 15 (12.5%) had no remission. Based on this study, the presence of laryngeal MMP seems to predict refractoriness to RTX treatment. In conclusion, we found that RTX can ameliorate the MMP course and that laryngeal involvement, which is known to be a prognostic factor for severe MMP, may also predict poor response to RTX.
Substances chimiques
Immunologic Factors
0
Rituximab
4F4X42SYQ6
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
915-919Informations de copyright
© 2021 British Association of Dermatologists.
Références
Amber KT, Murrel DF, Schmidt E et al. Autoimmune subepidermal bullous diseases of the skin and mucosae: clinical features. Clin Rev Allergy Immunol 2018; 54: 26-51.
Chan LS, Ahmed AR, Anhalt GJ et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment and prognostic indicators. Arch Dermatol 2002; 138: 370-9.
Murrell DF, Marinovic B, Caux F et al. Definitions and outcome measures for mucous membrane pemphigoid: recommendations of an international panel of experts. J Am Acad Dermatol 2015; 72: 168-74.
Lee L, Kukreti V. Rituximab-induced coronary vasospasm. Case Rep Hematol 2012; 2012: 984986.
Taverna JA, Lerner A, Bhawan J, Demierre MF. Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab. J Drugs Dermatol 2007; 6: 731-2.
Schumann T, Schmidt E, Booken N et al. Successful treatment of mucous membrane pemphigoid with the anti-CD-20 antibody rituximab. Acta Derm Venereol 2009; 89: 101-2.
Wollina U, Koch A, Hansel G. Rituximab therapy of recalcitrant bullous dermatoses. J Dermatol Case Rep 2008; 2: 4-7.
Ross AH, Jaycock P, Cook SD et al. The use of rituximab in refractory mucous membrane pemphigoid with severe ocular involvement. Br J Ophthalmol 2009; 93: 421-2.
Foster CS, Chang PY, Ahmed AR. Combination of rituximab and intravenous immunoglobulin for recalcitrant ocular cicatricial pemphigoid: a preliminary report. Ophthalmology 2010; 117: 861-9.
Li Y, Foshee JB, Sontheimer RD. Sustained clinical response to rituximab in a case of life-threatening overlap subepidermal autoimmune blistering disease. J Am Acad Dermatol 2011; 64: 773-8.
Lourari S, Herve C, Doffoel-Hantz V et al. Bullous and mucous membrane pemphigoid show a mixed response to rituximab: experience in seven patients. J Eur Acad Dermatol Venereol 2011; 25: 1238-40.
Schmidt E, Seitz CS, Benoit S et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol 2007; 156: 352-6.
Le Roux-Villet C, Prost-Squarcioni C, Alexandre M et al. Rituximab for patients with refractory mucous membrane pemphigoid. Arch Dermatol 2011; 147: 843-9.
Kasperkiewicz M, Shimanovich I, Ludwig RJ et al. Rituximab for treatment-refractory pemphigus and pemphigoid: a case series of 17 patients. J Am Acad Dermatol 2011; 65: 552-8.
Recke A, Shimanovich I, Steven P et al. [Treatment-refractory anti-laminin 332 mucous membrane pemphigoid. Remission following adjuvant immunoadsorption and rituximab] (in German). Hautarzt 2011; 62: 852-8.
Kolesnik M, Becker E, Reinhold D et al. Treatment of severe autoimmune blistering skin diseases with combination of protein A immunoadsorption and rituximab: a protocol without initial high dose or pulse steroid medication. J Eur Acad Dermatol Venereol 2014; 28: 771-80.
Wollina U, Pabst F, Kuss H et al. Monoclonal anti-CD20 antibody therapy in cicatrical pemphigoid with oral and hypopharyngeal involvement and related conditions. J Clin Aesthet Dermatol 2013; 6: 45-8.
Heelan K, Walsh S, Shear NH. Treatment of mucous membrane pemphigoid with rituximab. J Am Acad Dermatol 2013; 69: 310-11.
Nishimura R, Fujimoto N, Kito K et al. Refractory mucous membrane pemphigoid which developed after allogeneic stem cell transplantation and was successfully treated with rituximab. Eur J Dermatol 2013; 23: 562-4.
Tazudeen N, Au S, Pewitt J et al. IgM ocular cicatricial pemphigoid: a unique insight into the immune system. Dermatol Online J 2015; 21: 13030/qt40z314gz.
Maley A, Warren M, Haberman I et al. Rituximab combined with conventional therapy versus conventional therapy alone for the treatment of mucous membrane pemphigoid (MMP). J Am Acad Dermatol 2016; 74: 835-40.
Steger B, Madhusudan S, Kaye SB et al. Combined use of rituximab and intravenous immunoglobulin for severe autoimmune cicatricial conjunctivitis-an interventional case series. Cornea 2016; 35: 1611-14.
Haefliger S, Horn MP, Suter VG et al. Rituximab for the treatment of isolated refractory desquamative gingivitis due to mucous membrane pemphigoid. JAMA Dermatol 2016; 152: 1396-8.
Wilder E, Fernandez MP, Krejci-Manwaring J. Mucous membrane pemphigoid involving the trachea and bronchi: an extremely rare and life-threatening presentation. Cutis 2016; 98: E24-7.
You C, Lamba N, Lasave AF et al. Rituximab in the treatment of ocular cicatricial pemphigoid: a retrospective cohort study. Graefes Arch Clin Exp Ophthalmol 2017; 255: 1221-8.
Lambiel S, Dulguerov P, Laffitte E, Leuchter I. Paraneoplastic mucous membrane pemphigoid with ocular and laryngeal involvement. BMJ Case Rep 2017; 2017: bcr2017220887.
Witte M, Zillikens D, Shimanovich I. Intravenous immunoglobulins for rituximab-resistant mucous membrane pemphigoid. J Eur Acad Dermatol Venereol 2018; 32: e321-4.
Lamberts A, Euverman HI, Terra JB et al. Effectiveness and safety of rituximab in recalcitrant pemphigoid diseases. Front Immunol 2018; 9: 248.
Huff SB, Vasu S, Kaffenberger BH. Epitope spread in chronic mucosal GVHD: mucous membrane pemphigoid resolution with rituximab. Int J Dermatol 2019; 58: 240-1.
Hügel R, Lang A, Lhotta K et al. Anti-laminin 332 mucous membrane pemphigoid with laryngeal involvement - adjuvant treatment with immunoadsorption and rituximab. J Dtsch Dermatol Ges 2018; 16: 897-900.
Wijaya C, Morgan L, Novakovic D, Riminton S. Laryngoceles with airway compromise complicating mucous membrane pemphigoid. BMJ Case Rep. 2018; 2018: bcr2018225316.
Wittenberg M, Worm M. Severe refractory paraneoplastic mucous membrane pemphigoid successfully treated with rituximab. Front Med (Lausanne) 2019; 6: 8.
Flores-Climente V, Rozas-Muñoz E, Martínez-Grau A et al. Childhood ocular mucous membrane pemphigoid successfully treated with rituximab. Pediatr Dermatol 2019; 36: 984-5.
Dastmalchi D, Moslemkhani S, Bayat M et al. The efficacy of rituximab in patients with mucous membrane pemphigoid. J Dermatolog Treat 2020; 11: 1-7.
Alexandre M, Brette MD, Pascal F et al. A prospective study of upper aerodigestive tract manifestations of mucous membrane pemphigoid. Medicine (Baltimore) 2006; 85: 239-52.
Hertl M, Jedlickova H, Pemphigus KS et al. S2 Guideline for diagnosis and treatment-guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol 2015; 29: 405-14.
Sanchez J, Ingen-Housz-Oro S, Chosidow O et al. Rituximab as single long-term maintenance therapy in patients with difficult-to-treat pemphigus. JAMA Dermatol 2018; 154: 363-5.